

TEST REQUISITION FORM

SOLID ONCOLOGY

PATIENT DETAILS

Full Name _____ Age _____
 Sex Male Female Others **Ethnicity** _____
 E-mail ID* _____ Contact No. _____
 Address _____
 City / State / Postal Code _____ Country _____

REFERRING CLINICIAN

Physician Name _____
 Facility Name _____
 Facility Address _____
 City / State / Postal Code _____ Country _____
 E-mail ID _____ Contact No. _____
 Additional Physician to be Copied(optional) _____
 Facility Name _____
 E-mail ID _____ Contact No. _____

CLINICAL DETAILS

Diagnosis : NSCLC Melanoma Colorectal Adenocarcinoma Ovarian Breast
 Other _____
Disease Status (select as many as apply) : Metastatic Recurrent Refractory Relapse
 Subtype _____ Stage _____
 Radiological Findings : _____
 Immunohistochemistry Study Report : _____
 ER, PR, Her2 /Neu Status : _____
 Previous Genetic Tests /Targeted Therapies (if any)/ (Please mention the results)

Please attach the below reports to the TRF : (if Available)

Attachments :

- Copy of recent Pathology /Cytology reports
- Test results from all other Molecular Diagnostic Assays by FISH, IHC, or other genetic assays, e.g., ER, PR, HER2, EGFR, KRAS, etc.

TEST SELECTION

- | | |
|--|--|
| <input type="checkbox"/> OncoCEPT Solid (*FFPE block containing tumor tissue) | <input type="checkbox"/> OncoCEPT Liquid (*10ml Whole blood EDTA in streck tube) |
| <input type="checkbox"/> OncoCEPT Comprehensive (*FFPE block containing tumor tissue) | <input type="checkbox"/> MSI (*FFPE blocks with slides + EDTA blood) |
| <input type="checkbox"/> ColoComprehensive (MSI+BRAF+KRAS+NRAS) (*FFPE block containing tumor tissue) | <input type="checkbox"/> MMR by IHC |
| <input type="checkbox"/> PDL-1 test <input type="checkbox"/> PDL1 SP142 <input type="checkbox"/> PDL1 SP 263 | <input type="checkbox"/> PDL1 22C3 DAKO (#Drug details) |
| <input type="checkbox"/> OncoCEPT Solid + PDL1 | <input type="checkbox"/> OncoCEPT Solid Comprehensive + PDL1 |
| <input type="checkbox"/> Other test : Description of test & sample type _____ | |

In case of inadequate tissue, please tick the test which test would you like us to do first:

- OncoCEPT Solid OncoCEPT Solid Comprehensive PDL-1

Drug details for PDL-1 IHC

(PDL-1 IHC indicated in patients with specific tumor type in order to predict their responses to treatment with PDL-1 inhibitors. The specific PDL-1 clone scoring method and eligibility requirements are dependent on the tumor type, stage of malignancy, previous treatment outcomes and specific PDL-1 inhibitors being considered)

Tick	Clone	Drug
	Sp263	Nivolumab (opdivo)
	Sp263	Durvalumab (imfinzi)
	Sp142	Atezolilumab (Tecentriq)
	Sp142	Atezolilumab (Tecentriq)
	Sp142	Atezolilumab (Tecentriq) Plus nab- paclitaxel (Abaxane)
	22C3 DAKO	Pembrolizumab (Keytruda)

SAMPLE DETAILS

Collection Date _____ Collection Time _____ Specimen ID _____

- FFPE of tumour tissue (BIOPSY fixed in 10% Neutral buffered formalin)
Specimen Site _____
No. of paraffin blocks and details: _____
Please mention block number on which test has to be performed _____
- Body Fluid (At least 1 litre) or cell block
- FFPE BLOCK of tumor tissue (BIOPSY fixed in 10% Neutral buffered formalin) with HE stained slide
Specimen Site _____
- Unstained poly L lysine coated slides

Cold ischaemia time - _____ mins or hrs or unknown (As time of transfer of tissue after removal from body upto immersion into the 10% neutral buffered formalin)

Time Formalin fixation (10% neutral buffered formalin): known: _____ hours / unknown

Please Note :

- Neuberg Center for Genomic Medicine (NCGM) chooses the best block(s) based on initial morphologic assessment for further IHC PDL- 1 study . It makes all efforts to preserve and makes sure not to exhaust the tissue entirely under study. However in small thin/tiny specimen, there is a possibility of exhausting the tissue to ensure quality and reliability of the results.
- CAP/ASCO recommendation: for breast markers and GI Her2neu, the cold ischemic time should be < 01 hours and optimal fixation for ER/PgR/Her2Neu in 10% buffered formalin MUST be 06 to 72 hours

FAMILY HISTORY OF ANY CANCER

Sr. No.	Type of Cancer	Age of diagnosis	Relationship with patient	Mother's or father's side	Histopathology / genetic test reports (if available)

PHYSICIAN CONSENT

I certify that I am patient's treating physician and I consent that this test will aid in patient's ongoing treatment.

I have explained the patient about nature and purpose of testing. Patient has given his consent to me for Neuberg Center for Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature_____
Printed Name_____
Date: DD/MM/YY**PATIENT CONSENT**

I certify that I have been explained by my physician that this test will aid in my ongoing treatment/management.

I have been explained about nature and purpose of testing. I give my consent to Neuberg Center of Genomic Medicine to

- (1) Perform tests mentioned here.
- (2) Retain the test results.
- (3) De-identify the test report/ result for future research purpose and publication.

I authorize Neuberg Center of Genomic Medicine to perform most appropriate test based on submitted histopathology report.

Signature_____
Printed Name_____
Date: DD/MM/YY